Setmelanotide
Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome
Rhythm · Phase 2 · Completed · Enrollment 40
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Setmelanotide 0.5 mg | n/r | n/r | n/r | n/r |
| Setmelanotide 1.5 mg | n/r | n/r | n/r | n/r |
| Setmelanotide 2.5 mg | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r |
Not shown
- Setmelanotide 0.5 mg: endpoint not reported
- Setmelanotide 1.5 mg: endpoint not reported
- Setmelanotide 2.5 mg: endpoint not reported
- Placebo: endpoint not reported